Ovine dendritic cells transduced with an adenoviral CTLA4 e EGFP fusion protein construct induce hyporesponsiveness to allostimulation

Summary CTLA4 (CD152) is a transmembrane molecule expressed on activated T cells and functions as a negative regulator of T cell activation upon binding to the costimulatory molecules CD80/86. In this study, CTLA4 e EGFP constructs were engineered by cloning the extracellular domains of ovine and human CTLA4 (CTLA4 e ) ‘in frame’ with the enhanced green fluorescent protein (EGFP). Recombinant adenoviral vectors were generated by incorporation of the CTLA4 e EGFP sequence into the adenoviral genome using homologous recombination in Esherichia coli . The functional activity of the adenoviral vectors was shown by the secretion of the CTLA4 e EGFP upon infection of ovine fibroblasts and the binding of the fusion protein to the target ovine and human dendritic cells expressing CD80/86 receptors by flow cytometry. The EGFP tag facilitated molecular size determinations and quantification of the secreted ovine CTLA4 fusion protein by immunoprecipitation and enzyme‐linked immunosorbent assay (ELISA), respectively, using anti‐GFP mAbs. Ovine dendritic cells obtained from pseudoafferent lymphatic cannulation of sheep were characterized based on high major histocompatibility complex (MHC) class II expression and cross‐reactivity with monoclonal antibodies to the human dendritic cell markers, CD83 and CMRF‐56. In addition, ovine dendritic cells (DC) were transfected with the adenoviral CTLA4 e EGFP and when used as stimulators in a mixed lymphocyte reaction showed a reduced capacity to induce allogeneic lymphocyte proliferation. This study verifies that the ovine CTLA4 e EGFP fusion protein functions similarly to its human homologue and that DC modified with adenoviral CTLA4‐EGFP may provide an effective therapeutic approach in targeting alloreactive T cells to prolong allograft acceptance in a preclinical ovine model of renal transplantation.